Endothelial-monocyte activating polypeptide II disrupts alveolar epithelial type II to type I cell transdifferentiation

Yao Chen, Susan K. Legan, Anne Mahan, Janet Thornton, Haiming Xu, Margaret A. Schwarz

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Distal alveolar morphogenesis is marked by differentiation of alveolar type (AT)-II to AT-I cells that give rise to the primary site of gas exchange, the alveolar/vascular interface. Endothelial-Monocyte Activating Polypeptide (EMAP) II, an endogenous protein with anti-angiogenic properties, profoundly disrupts distal lung neovascularization and alveolar formation during lung morphogenesis, and is robustly expressed in the dysplastic alveolar regions of infants with Bronchopulmonary dysplasia. Determination as to whether EMAP II has a direct or indirect affect on ATII→ATI trans-differentiation has not been explored.Method: In a controlled nonvascular environment, an in vitro model of ATII→ATI cell trans-differentiation was utilized to demonstrate the contribution that one vascular mediator has on distal epithelial cell differentiation.Results: Here, we show that EMAP II significantly blocked ATII→ATI cell transdifferentiation by increasing cellular apoptosis and inhibiting expression of ATI markers. Moreover, EMAP II-treated ATII cells displayed myofibroblast characteristics, including elevated cellular proliferation, increased actin cytoskeleton stress fibers and Rho-GTPase activity, and increased nuclear:cytoplasmic volume. However, EMAP II-treated cells did not express the myofibroblast markers desmin or αSMA.Conclusion: Our findings demonstrate that EMAP II interferes with ATII → ATI transdifferentiation resulting in a proliferating non-myofibroblast cell. These data identify the transdifferentiating alveolar cell as a possible target for EMAP II's induction of alveolar dysplasia.

Original languageEnglish (US)
Article number1
JournalRespiratory Research
Volume13
DOIs
StatePublished - Jan 3 2012

Fingerprint

Cell Transdifferentiation
Alveolar Epithelial Cells
Myofibroblasts
Morphogenesis
Blood Vessels
Cell Differentiation
Controlled Environment
Bronchopulmonary Dysplasia
Lung
Stress Fibers
rho GTP-Binding Proteins
Desmin
small inducible cytokine subfamily E, member 1
Actin Cytoskeleton
Gases
Epithelial Cells
Cell Proliferation
Apoptosis

Keywords

  • Alveolar epithelial cell
  • Emap II
  • Transdifferentiation

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Endothelial-monocyte activating polypeptide II disrupts alveolar epithelial type II to type I cell transdifferentiation. / Chen, Yao; Legan, Susan K.; Mahan, Anne; Thornton, Janet; Xu, Haiming; Schwarz, Margaret A.

In: Respiratory Research, Vol. 13, 1, 03.01.2012.

Research output: Contribution to journalArticle

Chen, Yao ; Legan, Susan K. ; Mahan, Anne ; Thornton, Janet ; Xu, Haiming ; Schwarz, Margaret A. / Endothelial-monocyte activating polypeptide II disrupts alveolar epithelial type II to type I cell transdifferentiation. In: Respiratory Research. 2012 ; Vol. 13.
@article{313c127040c8485089c83b0d7e05405f,
title = "Endothelial-monocyte activating polypeptide II disrupts alveolar epithelial type II to type I cell transdifferentiation",
abstract = "Background: Distal alveolar morphogenesis is marked by differentiation of alveolar type (AT)-II to AT-I cells that give rise to the primary site of gas exchange, the alveolar/vascular interface. Endothelial-Monocyte Activating Polypeptide (EMAP) II, an endogenous protein with anti-angiogenic properties, profoundly disrupts distal lung neovascularization and alveolar formation during lung morphogenesis, and is robustly expressed in the dysplastic alveolar regions of infants with Bronchopulmonary dysplasia. Determination as to whether EMAP II has a direct or indirect affect on ATII→ATI trans-differentiation has not been explored.Method: In a controlled nonvascular environment, an in vitro model of ATII→ATI cell trans-differentiation was utilized to demonstrate the contribution that one vascular mediator has on distal epithelial cell differentiation.Results: Here, we show that EMAP II significantly blocked ATII→ATI cell transdifferentiation by increasing cellular apoptosis and inhibiting expression of ATI markers. Moreover, EMAP II-treated ATII cells displayed myofibroblast characteristics, including elevated cellular proliferation, increased actin cytoskeleton stress fibers and Rho-GTPase activity, and increased nuclear:cytoplasmic volume. However, EMAP II-treated cells did not express the myofibroblast markers desmin or αSMA.Conclusion: Our findings demonstrate that EMAP II interferes with ATII → ATI transdifferentiation resulting in a proliferating non-myofibroblast cell. These data identify the transdifferentiating alveolar cell as a possible target for EMAP II's induction of alveolar dysplasia.",
keywords = "Alveolar epithelial cell, Emap II, Transdifferentiation",
author = "Yao Chen and Legan, {Susan K.} and Anne Mahan and Janet Thornton and Haiming Xu and Schwarz, {Margaret A.}",
year = "2012",
month = "1",
day = "3",
doi = "10.1186/1465-9921-13-1",
language = "English (US)",
volume = "13",
journal = "Respiratory Research",
issn = "1465-9921",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Endothelial-monocyte activating polypeptide II disrupts alveolar epithelial type II to type I cell transdifferentiation

AU - Chen, Yao

AU - Legan, Susan K.

AU - Mahan, Anne

AU - Thornton, Janet

AU - Xu, Haiming

AU - Schwarz, Margaret A.

PY - 2012/1/3

Y1 - 2012/1/3

N2 - Background: Distal alveolar morphogenesis is marked by differentiation of alveolar type (AT)-II to AT-I cells that give rise to the primary site of gas exchange, the alveolar/vascular interface. Endothelial-Monocyte Activating Polypeptide (EMAP) II, an endogenous protein with anti-angiogenic properties, profoundly disrupts distal lung neovascularization and alveolar formation during lung morphogenesis, and is robustly expressed in the dysplastic alveolar regions of infants with Bronchopulmonary dysplasia. Determination as to whether EMAP II has a direct or indirect affect on ATII→ATI trans-differentiation has not been explored.Method: In a controlled nonvascular environment, an in vitro model of ATII→ATI cell trans-differentiation was utilized to demonstrate the contribution that one vascular mediator has on distal epithelial cell differentiation.Results: Here, we show that EMAP II significantly blocked ATII→ATI cell transdifferentiation by increasing cellular apoptosis and inhibiting expression of ATI markers. Moreover, EMAP II-treated ATII cells displayed myofibroblast characteristics, including elevated cellular proliferation, increased actin cytoskeleton stress fibers and Rho-GTPase activity, and increased nuclear:cytoplasmic volume. However, EMAP II-treated cells did not express the myofibroblast markers desmin or αSMA.Conclusion: Our findings demonstrate that EMAP II interferes with ATII → ATI transdifferentiation resulting in a proliferating non-myofibroblast cell. These data identify the transdifferentiating alveolar cell as a possible target for EMAP II's induction of alveolar dysplasia.

AB - Background: Distal alveolar morphogenesis is marked by differentiation of alveolar type (AT)-II to AT-I cells that give rise to the primary site of gas exchange, the alveolar/vascular interface. Endothelial-Monocyte Activating Polypeptide (EMAP) II, an endogenous protein with anti-angiogenic properties, profoundly disrupts distal lung neovascularization and alveolar formation during lung morphogenesis, and is robustly expressed in the dysplastic alveolar regions of infants with Bronchopulmonary dysplasia. Determination as to whether EMAP II has a direct or indirect affect on ATII→ATI trans-differentiation has not been explored.Method: In a controlled nonvascular environment, an in vitro model of ATII→ATI cell trans-differentiation was utilized to demonstrate the contribution that one vascular mediator has on distal epithelial cell differentiation.Results: Here, we show that EMAP II significantly blocked ATII→ATI cell transdifferentiation by increasing cellular apoptosis and inhibiting expression of ATI markers. Moreover, EMAP II-treated ATII cells displayed myofibroblast characteristics, including elevated cellular proliferation, increased actin cytoskeleton stress fibers and Rho-GTPase activity, and increased nuclear:cytoplasmic volume. However, EMAP II-treated cells did not express the myofibroblast markers desmin or αSMA.Conclusion: Our findings demonstrate that EMAP II interferes with ATII → ATI transdifferentiation resulting in a proliferating non-myofibroblast cell. These data identify the transdifferentiating alveolar cell as a possible target for EMAP II's induction of alveolar dysplasia.

KW - Alveolar epithelial cell

KW - Emap II

KW - Transdifferentiation

UR - http://www.scopus.com/inward/record.url?scp=84855228079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855228079&partnerID=8YFLogxK

U2 - 10.1186/1465-9921-13-1

DO - 10.1186/1465-9921-13-1

M3 - Article

VL - 13

JO - Respiratory Research

JF - Respiratory Research

SN - 1465-9921

M1 - 1

ER -